Ferring SA de CV
$18.0K 10 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Solco Biomedical Corporation
Solco Biomedical Corporation reported $18,000.00 across General Payments, Research, and Ownership to 11 physicians and teaching hospitals across 11 transactions.
- $18.0K Below-median payer
- All-tracks total
- 11 Below-median volume
- Transactions
- 11 Below-median reach
- Recipients
- −$8.6K
- General Payments vs PY2023
Solco Biomedical Corporation reported $18,000.00 across all CMS Open Payments tracks (General + Research + Ownership) to 11 physicians and teaching hospitals in Program Year 2024 - ranking #1549 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $18,000.00, averaging $1.6K per recipient.
Solco Biomedical Corporation's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
13/100
Total payments
F
10/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer solco-biomedical-corporation Solco Biomedical Corporation
$18.0K · #1549/1,925 · 0.0% industry · PY2024
- TOT $18.0K
- RANK #1549
- SHARE 0.0%
- TXN 11
- RCP 11
- CAT 2
- GEN $18.0K
- ΔGEN −$8.6K
- TOP1 68.9%
- PY 2024
Volume peers
Nearest volume peer: Ferring SA de CV ($18.0K)
Solco Biomedical Corporation sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Solco Biomedical Corporation's CMS-reported General Payments decreased by $8.6K (−32.3%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: SOLCO BIOMEDICAL CORPORATIONPY2023: SOLCO BIOMEDICAL CORPORATIONPY2024: Solco Biomedical Corporation. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $26,596.55
- PY2024
- $18,000.00
What the Data Shows for Solco Biomedical Corporation
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Solco Biomedical Corporation that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
9 transactions worth $11.4K make "Consulting Fee" the top general-payment category in the 2-category breakdown below, 63.3% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Consulting Fee" leads Solco Biomedical Corporation's 2-category general-payment breakdown at $11.4K, 63.3% of the reported total.
How Solco Biomedical Corporation divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $11.4K | 9 | 63.3% |
| Travel and Lodging | $6.6K | 2 | 36.7% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $18,000.00 (100.0%) of $18,000.00 in this company's General Payments records across 5 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Solco Biomedical Corporation
The five named recipients with the highest reported General Payments from this company
- 1
Michael Oh
$12,400.00 across 7 reported transactions
- 2
Richard Davis
$3,600.00 across 1 reported transactions
- 3
Hooman Melamed
$1,100.00 across 1 reported transactions
- 4
Paul Salinas
$600.00 across 1 reported transactions
- 5
Kevin Yoo
$300.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Solco Biomedical Corporation ranks #1549 of 1,925 by total payments (bottom 20% by spend) but is notably more concentrated than that alone would suggest -- #332 of 1,838 by HHI (top 18% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Vifor Fresenius Medical Care Renal Pharma Ltd. : $5.0K total payments, HHI 5225
- Roche Sequencing Solutions, Inc. : $14.3K total payments, HHI 5222
- Northgate Technologies, Inc. : $21.4K total payments, HHI 5218
- Janssen Products, LP : $473.97 total payments, HHI 5203
- SPIWay, LLC : $7.0K total payments, HHI 5200
- Forthright Medical - MT, LLC : $100.4K total payments, HHI 5198
- Solco Biomedical Corporation (this company) : $18.0K total payments, HHI 5197
- Zentech Inc. : $15.2K total payments, HHI 5181
- Ipsen Pharma SAS : $456.4K total payments, HHI 5180
- Omega Medical Imaging, LLC : $515.98 total payments, HHI 5180
- Dental Material Gesellschaft mbH : $7.3K total payments, HHI 5160
- Aspero Medical, Inc. : $1.4K total payments, HHI 5153
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Solco Biomedical Corporation's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Solco Biomedical Corporation.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Solco Biomedical Corporation.
Showing 6 of 1,924 companies with CMS-reported payment data.
Centrix Inc
$17.9K 157 recipients
Compare payment profiles
Avantec Vascular Corporation
$17.9K 48 recipients
Compare payment profiles
Ostial Corporation
$18.2K 168 recipients
Compare payment profiles
Bayer Puerto Rico Inc.
$18.3K 821 recipients
Compare payment profiles
Jubilant DraxImage Inc.
$17.7K 9 recipients
Compare payment profiles
Put this to use
Solco Biomedical Corporation ranks #1549 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Solco Biomedical Corporation. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.